Pharvaris’ deucrictibant shows rapid relief for hereditary angioedema in pivotal Phase 3 trial

The study met its primary endpoint and all 11 secondary efficacy endpoints

Roche presents positive phase III data for vamikibart in uveitic macular edema

Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME

FDA approves Corstasis’ bumetanide nasal spray to treat edema in heart, liver, and kidney disease

FDA approved Dawnzera in US as first and only RNA-targeted prophylactic treatment for hereditary angioedema

Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control

Long-term efficacy and safety profile of Eylea 8 mg with extended dosing intervals in diabetic macular edema confirmed at three years

Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years

Takeda launches CINRYZE in India for hereditary angioedema patients

CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.

Cadila Pharma launches triple-combination therapy for stronger BP control

The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms

Innovent Biologics’ OLN324 shows breakthrough results in vision disease study

The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred

Merck launches high-stakes trial of dual-action eye drug aiming to halt leading cause of blindness

The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year

Bayer plans to offer Eylea 2mg at lower cost in India for benefit of retinal disease patients

Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina